PLoS ONE (Jan 2014)

Properly substituted analogues of BIX-01294 lose inhibition of G9a histone methyltransferase and gain selective anti-DNA methyltransferase 3A activity.

  • Dante Rotili,
  • Domenico Tarantino,
  • Biagina Marrocco,
  • Christina Gros,
  • Véronique Masson,
  • Valérie Poughon,
  • Fréderic Ausseil,
  • Yanqi Chang,
  • Donatella Labella,
  • Sandro Cosconati,
  • Salvatore Di Maro,
  • Ettore Novellino,
  • Michael Schnekenburger,
  • Cindy Grandjenette,
  • Celine Bouvy,
  • Marc Diederich,
  • Xiaodong Cheng,
  • Paola B Arimondo,
  • Antonello Mai

DOI
https://doi.org/10.1371/journal.pone.0096941
Journal volume & issue
Vol. 9, no. 5
p. e96941

Abstract

Read online

Chemical manipulations performed on the histone H3 lysine 9 methyltransferases (G9a/GLP) inhibitor BIX-01294 afforded novel desmethoxyquinazolines able to inhibit the DNA methyltransferase DNMT3A at low micromolar levels without any significant inhibition of DNMT1 and G9a. In KG-1 cells such compounds, when tested at sub-toxic doses, induced the luciferase re-expression in a stable construct controlled by a cytomegalovirus (CMV) promoter silenced by methylation (CMV-luc assay). Finally, in human lymphoma U-937 and RAJI cells, the N-(1-benzylpiperidin-4-yl)-2-(4-phenylpiperazin-1-yl)quinazolin-4-amine induced the highest proliferation arrest and cell death induction starting from 10 µM, in agreement with its DNMT3A inhibitory potency.